Developing clinical trials in the portuguese family medicine : challenges and opportunities in the European context by Pereira, Manuel Pedro dos Santos Rodrigues
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Master of Science Thesis 
 
Developing 
Clinical Trials in 
The Portuguese 
Family Medicine 
 
Challenges and 
Opportunities in the 
European Context 
 
 
 
Master of Science Candidate: 
Manuel Pedro dos Santos Rodrigues Pereira 
 
 
 
Advisor: Pedro Afonso Caetano 
 
2014 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
3 
Acknowledgements 
 
Adriana Rubín; Alexandre Gouveia; Ana Cardoso; Ana Costa; Ana Dantas; 
Ana Esperança; Ana Ferreira; Ana Vasconcellos Fino; Ana Rita Jesus Maria; 
Ana Sá; Ana Viegas; André Correa; Andreia Priscila Araújo; Ângela 
Cerqueira; Ângelo Abel; António Vaz Carneiro; Armando Brito de Sá; Bruno 
Cerca; Carla Gouveia; Carlos Martins; Carlos Pedro Mendes; Carolina 
Pereira; Catarina Bernardes; Catarina Godinho; Christos Leonis; Daniel 
Castro; Daniel Pinto; Daniela Eugénio; David Silvério Rodrigues; Denise 
Alexandra; Dilermando Sobral; Edgar Ferreira; Edmundo Sá; Emília 
Monteiro; Fátima Rabaçal; Fernando Delgado; Fernando Ferreira; Filipa 
Nóbrega; Filipa Prazeres; Francisco Gouveia; Frederico Rosário; Gabriel 
Rodrigues Pereira; Gabriela Poças; Guilherme Amaral Mendes; Hélder 
Sousa; Hugo Bento Sousa; Inês Espiga Macedo; Inês Rosendo; Isabel 
Lourenço Ribeiro; Isabel Pinto; Isabela Carvallho; Jaime Brito da Torre; 
Jaime Correia de Sousa; Joana Neto; João Adélo Trocado Moreira; João 
Manuel Silva; João Nuno Rossa; João Ribeiro; José Augusto Simões; José 
Manuel Silva; José Mendonça; José Miguel Guimarães; José Silva Henriques; 
Josef Räder; Liliana Laranjo; Luís Filipe Gomes; Luís Pisco; Luíz Miguel 
Santiago; Mafalda Calmeiro Santos; Margarida Nunes da Silva; Margarida 
Santos Lima Brandão; Maria Manuel Marques; Marisa Freire; Marta 
Magalhães; Marta Marquês; Miguel Azevedo; Mónica Granja; Natacha 
Murinello; Nélson Romão de Brito; Nuno Florêncio; Nuno Pina; Paula 
Miranda; Pedro Carrilho; Raquel Barros; Raquel Braga; Raquel Magalhães; 
Raquel Nadais; Rita Tato; Rita Viegas; Rizério Salgado; Rui Garcia; Rui 
Oliveira; Rui Pedro Amendoeira; Salomé S. Coutinho; Susana Pereira da 
Costa; Susana Ribeiro Trovão; Susete Simões; Teresa Libório; Tiago Sousa 
Veloso; Tracy Gouveia; Vera Carvalho; Vera Teles; Vítor Ramos. 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
4 
 
Table of Contents 
  
 
 
Table of Contents .......................................................................................................................... 4 
Keywords ..................................................................................................................................... 11 
Abstract ....................................................................................................................................... 12 
Resumo ........................................................................................................................................ 13 
1. Introduction: Hypothesis and the Need to Explore It ............................................................. 14 
2. Background .............................................................................................................................. 17 
2.1 Worldwide Principles of Family Medicine ......................................................................... 17 
2.2 Family Medicine in Portugal .............................................................................................. 18 
3. Methods .................................................................................................................................. 21 
4. Results ..................................................................................................................................... 22 
4.1 Literature Review and Interviews on Family Medicine Clinical Research ......................... 22 
4.1.1 Comprehensive Clinical Trials Report by PwC ............................................................ 23 
4.1.2 The Decline of the “Doctor-Scientist” ........................................................................ 24 
4.1.3 Subjects recruited in Primary Care Settings ............................................................... 26 
4.1.4 Challenges .................................................................................................................. 27 
4.1.5 Opportunities ............................................................................................................. 31 
4.1.6 Three Cases of Clinical Trials in the Portuguese Family Medicine ............................. 31 
4.2 Current European Strategies to Increase Clinical Trials .................................................... 32 
4.2.1 European Networks .................................................................................................... 34 
4.2.2 The United Kingdom Case .......................................................................................... 35 
4.3 Questionnaires on Family Medicine Clinical Research ...................................................... 36 
4.3.1 “Portuguese GPs and the Clinical Trials Questionnaire – 2012” ................................ 36 
4.3.2 “Portuguese GPs and Clinical Trials Questionnaire – 2014” ...................................... 50 
4.3.3 “Improving Clinical Trials in Portuguese Family Medicine” – The Vision of 15 Key 
Opinion Leaders .................................................................................................................. 53 
5. Discussion ................................................................................................................................ 56 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
5 
6. Conclusion / Recommendations ............................................................................................. 57 
6.1 To Provide Time................................................................................................................. 57 
6.2 To Finance ......................................................................................................................... 57 
6.3 To Support ......................................................................................................................... 58 
7. References .............................................................................................................................. 60 
8. Attachments ............................................................................................................................ 62 
8.1. Attachment 1 – “Portuguese GPs and the Clinical Trials Questionnaire – 2012” ............ 62 
8.2 Attachment 2 – “Doing Clinical Trials in the Portuguese Family Medicine Context” ....... 65 
8.3 Attachment 3 – “Clinical Trials and The Portuguese GPs Questionnaire – 2014” ............ 67 
8.4 Attachment 4 – “Improving Clinical Trials in Portuguese Family Medicine” - The Vision of 
15 Key Opinion Leaders ........................................................................................................... 68 
 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
6 
 
Figures Index 
 
 
Figure 1 – Map of Clinical Trials in Europe (Source: ClinicalTrials.gov consulted Jan. 2012 for 
Year 2011) ................................................................................................................................... 27 
Figure 2– Clinical Trials in Europe - Portugal at the European Bottom (Source: ClinicalTrials.gov 
consulted  Jan. 2012 for Year 2011) ............................................................................................ 29 
Figure 3– Did you ever had an interest in conducting clinical trials? ......................................... 37 
Figure 4 - Are you aware of the regulatory requirements to conduct a clinical trial? ................ 37 
Figure 5 - Do you know how to deal with the experimental drug during a trial? ....................... 38 
Figure 6 - Do you know what documents to submit to seek clinical trial approval? .................. 38 
Figure 7 - Do you know what good clinical (for research) practices are? ................................... 39 
Figure 8 – Do  you know the main rules and regulation to abide by during a clinical trial? ....... 39 
Figure 9 - Do you know what requirements you must fulfil to close a clinical trial? .................. 39 
Figure 10 - Do you know where to go to educate yourself about such requirements? ............. 40 
Figure 11 - Does your health centre have infrastructures for conducting clinical trials? ........... 40 
Figure 12– Would an academic career in clinical trials fulfil your role as a GP? ......................... 41 
Figure 13 - Do you think that the country can benefit from clinical trials? ................................ 41 
Figure 14 - Do you think the health system can benefit from clinical trials? .............................. 41 
Figure 15 - Pressure to see the maximum number of patients .................................................. 42 
Figure 16– Lack of support personnel ......................................................................................... 42 
Figure 17– Lack of financial initiatives ........................................................................................ 43 
Figure 18 - No clear rules for compensation of the time invested in research .......................... 43 
Figure 19– The bureaucracy dealing with INFARMED, CEIC or CNPD - too overwhelming for the 
time available to physicians, especially for those outside Lisbon who cannot deal directly with 
the regulatory managers (...) ...................................................................................................... 43 
Figure 20 - Once a doctor becomes a specialist in family medicine, he no longer has flexibility 
to manage his non-clinical work ................................................................................................. 44 
Figure 21 - To put Clinical Research and particularly Clinical Trials in the political agenda ....... 45 
Figure 22 - To establish a system of effective communication between clinical units and GP 
academic departments ............................................................................................................... 46 
Figure 23 - To delegate some routine family physician functions to other health professionals in 
order to gain physician's space and time for research and therefore not compromising the 
number of patient visits .............................................................................................................. 46 
Figure 24 - To contracting support staff (statisticians, nurses, administrative, etc.) specifically 
for research ................................................................................................................................. 46 
Figure 25 - To improve cooperation between clinical units and family medicine university 
departments ................................................................................................................................ 47 
Figure 26 - To inlvolve healthcare units in education and research networks ........................... 47 
Figure 27 - To give economical independence to health centres ............................................... 48 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
7 
Figure 28 - To finance the practicing clinicians in order to conduct research; having proctected 
time and being paid to work on studies ...................................................................................... 48 
Figure 29 - To obtain industry funds in a non-binding way to increase funds and support rooms, 
better equipment, even newer equipment, furniture, refurnishing walls, computers, without 
sacrificing the available budget ................................................................................................... 49 
 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
8 
 
Tables Index 
 
 
Table 1 – Sample Characterization .............................................................................................. 36 
Table 2 – Statistical Analysis for the answers to Question 1 ...................................................... 50 
Table 3 - Statistical Analysis for the answers to Question 2 ....................................................... 50 
Table 4 - Statistical Analysis for the answers to Question 3 ....................................................... 51 
Table 5 - Statistical Analysis for the answers to Question 4 ....................................................... 51 
Table 6 - Statistical Analysis for the answers to Question 5 ....................................................... 52 
Table 7 – The answers of the 15 Key Opinion Leaders Approached ........................................... 53 
 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
9 
 
Acronyms and Abbreviations 
 
 
ACES – Agrupamento de Centros de Saúde (En: Group of Health Centres) 
ACSS – Administração Central do Sistema de Saúde 
AMPIF – Associação de Médicos Portugueses da Indústria Farmacêutica 
APIFARMA – Associação Portuguesa da Indústria Farmacêutica (En: Portuguese Association of 
the Farmaceutical Industry) 
ARS – Administração Regional de Saúde (En: Regional Health Administration) 
BRIC – Brazil, Russia, India and China  
CEIC – Comissão de Ética para a Investigação Clínica (En: Ethics Committee for Clinical 
Research) 
CNPD – Comissão Nacional de Protecção de Dados (En: Data Protection National Comission) 
CPVO – Community Plant Variety Office  
EAHC – Executive Agency for Health and Consumers 
ECRIN – European Clinical Research Infrastructures Network  
ECDC – European Centre for Disease Prevention and Control 
ECHA – European Chemicals Agency 
EEA – European Environment Agency 
EFSA – European Food Safety Authority 
ENSP – Escola Nacional de Saúde Pública 
EGPRN – European General Practice Research Network 
EIT – European Institute of Innovation and Technology 
EMA – European Medicines Agency  
EMCDDA – European Monitoring Centre for Drugs and Drug Addiction 
ERC – European Research Council 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
10 
ETF – European Training Foundation 
EURACT – European Academy of Teachers of General Practice / Family Medicine 
EUROFOUND - European Foundation for the Improvement of Living and Working Conditions 
FCT – Fundação para a Ciência e Tecnologia 
FMUL – Faculdade de Medicina da Universidade de Lisboa 
GSK – Glaxo Smith Kline 
HPV – Human Papiloma Virus 
INFARMED – Autoridade Nacional do Medicamento e Produtos de Saúde (En: Portuguese 
National Authority for Drugs and Health Products) 
PNEC – Plataforma Nacional de Ensaios Clínicos (En: National Platform for Clinical Trials) 
PtCRIN - Portuguese Academic Clinical Trials Infrastructures Network   
PwC – PricewaterhouseCoopers Portugal 
REA – Research Executive Agency 
RPCG – Revista Portuguesa de Clínica Geral (Currently RPMGF; En: Portuguese Journal of 
General Practice) 
RPMGF – Revista Portuguesa de Medicina Geral e Familiar (Former RPCG; En: Portuguese 
Journal of Family Medicine) 
UCSP – Unidade de Cuidados de Saúde Personalizados (En: Personalized Health Care Unit) 
UKCRN – United Kingdom Clinical Research Network 
USF – Unidade de Saúde Familiar (En: Family Health Unit) 
WONCA – World Organization of National Colleges, Academies and Academic Associations of 
General Practitioners / Family Physicians 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
11 
 
 
Keywords 
 
Clinical Trials; Europe; Family Medicine; General Practice; Portugal. 
 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
12 
 
Abstract 
 
 
 
 
Introduction: The hypothesis of this thesis is that there could be a much greater number of 
Clinical Trials in Portuguese Family Medicine if obstacles were removed and opportunities 
explored properly. 
Background: In Portugal there is a new generation of Family Doctors that is assuming 
permanent positions all over the country and is accepted to be the most well prepared 
generation ever. 
Methods: Search on MEDLINE. Relevant articles were also identified in the only journal 
dedicated to Portuguese Family Medicine, RPMGF. A search was made on Portuguese 
health policy textbooks and national health plan policy. INFARMED was also contacted and 
their reports about Clinical Trials were analysed. Portuguese Family Doctors themselves 
were contacted and invited to answer questionnaires. Besides that, fifteen key opinion 
leaders related to Portuguese Medicine were approached for solutions. 
Results: According to INFARMED data, from 2006 to 2011 there were only four health 
centres involved in clinical trials. In Portugal there is: A negligible number of academic trials; 
almost no support infrastructures or training; inefficiently used electronic health records; a 
research weakly linked to medical careers; an uninformed isolation internally and 
externally; an already complex European Union regulation that is compounded even more; 
Scarce funding for clinical research. Portuguese Family Doctors are keen to actively 
participate in a change. 
Discussion: With the present results the diagnosis for the current situation is clearly 
negative. Fortunately there are very good opportunities to improve. 
Conclusion/Recommendations: Time, money and support must be given to Portuguese 
Family Doctors. In this context, twenty recommendations are provided intending to 
promote a true change in Portuguese Family Medicine Clinical Trials panorama. 
 
 
Keywords: Clinical Trials; Europe; Family Medicine; General Practice; Portugal. 
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Resumo 
 
 
 
 
Introdução: A hipótese colocada nesta tese é a de que poderia haver um número bastante 
mais elevado de ensaios clínicos na medicina familiar portuguesa se os obstáculos fossem 
removidos e as oportunidades exploradas de modo adequado. 
Contexto: Em Portugal existe uma nova geração de Médicos de Família que está a assumir 
postos de trabalho um pouco por todo o país e que é aceite como sendo a mais bem 
preparada geração de sempre.  
Métodos: Busca na MEDLINE. Leitura de artigos na única publicação científica dedicada à 
Medicina Geral e Familiar – RPMGF. Consulta em livros portugueses de política da saúde e 
acerca do Plano Nacional de Saúde. O INFARMED foi contactado e relatórios seus sobre 
ensaios clínicos foram analisados. Os Médicos de Família portugueses foram contactados e 
convidados a responder a questionários. Além disso, quinze personalidades da Medicina 
Portuguesa foram chamadas a sugerir soluções. 
Resultados: De acordo com dados do INFARMED, de 2006 a 2011 houve apenas quatro 
centros de saúde envolvidos em ensaios clínicos. Em Portugal: Existe um número pouco 
significativo de ensaios académicos; Praticamente não há infraestruturas de suporte ou 
treino; Os registos clínicos eletrónicos são usados de forma ineficiente; a investigação é 
fracamente ligada às carreiras médicas; há isolamento interno e externo; a já complexa 
regulamentação da União Europeia é complicada ainda mais; há um subfinanciamento da 
Investigação Clínica. Os Médicos de Família portugueses estão disponíveis para participar 
ativamente numa mudança.  
Discussão: Com os presentes resultados o diagnóstico para a presente situação é 
claramente negativo. Felizmente existem muito boas oportunidades para melhorar. 
Conclusão/Recomendações: Tempo, dinheiro e apoio têm de ser fornecidos aos Médicos 
de Família portugueses. É nesse sentido que são fornecidas vinte recomendações para 
obter uma verdadeira mudança no panorama dos Ensaios Clínicos na Medicina Familiar 
portuguesa. 
 
 
 
Palavras-Chave: Ensaios Clínicos; Europa; Medicina Familiar; Clínica Geral; Portugal. 
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1. Introduction: Hypothesis and 
the Need to Explore It 
 
 
 
 
 
he hypothesis of this thesis is that there could be a much greater number of 
clinical trials in Portuguese family medicine if obstacles were removed and 
opportunities explored properly. This work started with the belief that the 
confirmation of this hypothesis through sound methodology can lead to a set of 
implementable recommendations to increase the number and quality of clinical trials in family 
medicine in Portugal.  
 Family medicine is a scientific discipline recognized worldwide, where clinical 
practice, education and research should walk hand in hand for the benefit of patients. In 
Portugal it has advanced slowly but surely. First it conquered its space in clinical practice. 
Secondly it is establishing educational departments in medical schools. Thirdly it must increase 
its clinical research. It is in research that it significantly lacks behind other countries´ family 
medicine.  Research is crucial because if any scientific discipline ignores it then it is condemned 
to stagnation and deterioration. Therefore, it is in family medicine best interest to advance 
clinical research. 
Within the need to advance clinical research this thesis is focused specifically on 
clinical trials. This is because such trials are the most complex type of research and if they 
become routine, then the whole clinical research universe in family medicine will be improved.  
It is important to increase clinical trials across Portuguese medicine and it is also 
important to do research in primary care, so that it complements that done in hospitals. 
When studying a drug already in the market, with an ambulatory indication and with 
characteristics for primary care patients, there is not an excuse for not testing it in a family 
medicine setting. There are plenty of good and relevant research topics for family medicine. 
The true effectiveness of an innovation can only be judged in appropriately designed clinical 
trials conducted in the setting where the innovation will be applied. (Peterson, 2006) That is 
unquestionable. Research done in hospitals cannot always appropriately represent the 
community patients in which the drug will be used often and chronically.  
In order to develop Portugal’s Health Care System, there is a need to enhance the 
research capacity and to engage family doctors in clinical research. Only this option will 
promote the right questions to be asked, evaluating patient oriented outcomes. If research 
T
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becomes abundant then health outcomes will be studied and family medicine itself, as a 
technical and scientific discipline, will be significantly improved in the country. 
In the real world, real primary care patients have co morbidities, but most of the 
guidelines, have been developed based on studies ignoring co morbidities. (W. Beasley, 
Starfield, van Weel, W. Rosser, & L. Haq, 2007) This knowledge is an opportunity to develop 
clinical research in primary care settings with real world patients. While compliance is not 
considered as an outcome, researchers in primary care should also bear in mind that a lack of 
compliance in the “real world” frequently renders an efficacious intervention ineffective, and 
they should address this issue in their study design. This will usually involve consideration of 
additional social and emotional endpoints. (Lionis C, 2012) Family medicine research, with its 
focus on the person’s health and effective delivery of care, has a key role to play in bridging 
the gap between the laboratory and practice. (L. K. Lam, 2004) It is the only discipline which 
can do it spontaneously. With its holistic approach to medicine, family medicine approaches to 
patients with all their complexity of biologic, psychological and social factors. It deals with the 
real people in a real context – their communities – with all the co morbidities a doctor must 
deal with, including confounding factors that were never thought about previously by 
scientists far from the clinical setting and, by definition, with difficulties to identify problems in 
the passage from the bench to the patients’ bedside. The age of family medicine research will 
come when all medical research will require the input from family medicine to assure its 
validity, relevance, applicability, and generalizability. (L. K. Lam, 2004) 
How can Portuguese family medicine take the next steps in order to advance and 
achieve better results in clinical research? To answer that question, the low performing (in 
terms of clinical research) Portuguese primary care and other more prolific European primary 
care settings were analysed. Primary care clinical research in other European countries is 
flourishing. For example in England, networks are established and many doctors assume as 
part of their professional life that clinical research in general, and particularly clinical trials, do 
have interest. It is common to see stated clinical research activity interest when job vacancies 
are advertised for a GP practice. 
In 2014 there is a dearth of clinical trials in Portuguese family medicine. Clinical trials 
are almost inexistent. The few that have obtained regulatory approval (which does not mean 
that they were even able to recruit patients) were all sponsored by the pharmaceutical 
industry. Industry sponsored trials are well funded and provide the doctor investigator with 
guidance and resources from the company. Their weakness is that is mainly profit oriented so 
if the molecule patent has expired or, alternatively, if it is for few patients, then it will not be 
done. Investigator initiated (academic) trials complement such research by exploring questions 
that the industry does not want to, or has no interest in answering.  They have scarcer funding 
available and demand much more from the doctor who will have to design the protocol alone 
and deal with the overwhelming requirements.   Both types of trials are useful and at least in 
the beginning, it would be very useful if at least industry trials could flourish and, around them, 
infrastructures which would enable academic trials. However, family doctors cannot delegate 
research only in pharmaceutical companies. Family doctors cannot ignore research useful for 
patients just because they do not have, economically speaking, a commercially “interesting” 
problem for the industry. 
Other than the obvious dearth of trials, the background of clinical trials in Portuguese 
family medicine is almost inexistent. That is precisely why this thesis will, in the results section, 
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deliver an overview of family medicine trials by enquiry and review of the scarce material 
available. That is an important contribution of the present work.  Only if the problem is fully 
uncovered and explored can a solution begin to be constructed based on removing obstacles 
and exploring the opportunities to increase the trials. 
João Lobo Antunes classifies three types of advantages in having Clinical Research: 
1. Healthcare – better quality of care with faster access to innovative drugs; 
2. Educational and scientific – opportunity for researchers to collaborate with their peers 
in national and international programs; 
3. Economic – more jobs in research and development, acquiring new competences. 
In fact, these are inseparable and improve each other in an endless spiral. The best of all is the 
final result – a better society with a stronger economy, with outstanding healthcare quality 
constantly fed by an exciting ambience of innovation and high standards in research and 
education. 
It is long time known that a strong primary health care system is essential to provide 
effective and efficient health care. And it is also true that research in primary care is essential 
to inform practice and to develop better health systems and health policies. (W. Beasley, 
Starfield, van Weel, W. Rosser, & L. Haq, 2007) A country like Portugal must succeed in 
bringing family doctors to do clinical trials. The opposite is not even an option. The financial 
and economic crisis will have an end. Changing the status quo will then be crucial to Portugal 
affirm itself as a fully developed country with the ambition of becoming a world leader. 
Specifically, Clinical Trials have several advantages: 
• Keep health units updated on top care; 
• Provide new treatment options to patients; 
• Generate highly qualified jobs (doctor Investigators supported by research nurses, 
biostatisticians, database managers, investigational drug pharmacists, clinical monitors, 
regulatory managers, etc.); 
• (Academic ones) help translate into patient benefits from the work of basic researchers; 
• (Industry ones) are a significant source of income for countries and institutions clever, 
competitive and committed enough to attract them. 
There is a need to develop Clinical Trials in Portuguese family medicine. Change is the 
most natural thing in the world. When the current status is not appropriate, the wisest 
decision is to promote the evolution to something better. Continuous improvement is always 
recommendable. In order to ensure that clinical research rapidly and successfully advances 
practice, clinical researchers need to develop new partnerships with primary care providers 
who deliver the majority of care to the population. These partnerships should enhance the 
ability of investigators to conduct research, as well as facilitate delivery of better tools to 
clinicians to provide care. (Peterson, 2006) 
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2. Background 
 
 
t is important to develop a national program for research in health. The European 
scientific panorama in the health field is extremely vast, taking a leading role in 
the investment in research and development, coordinating the scientific national 
systems and promoting scientific excellence. (Campos & Simões, 2012) The absence of an 
effective primary care research infrastructure as it happens in countries like Portugal is 
impairing the development of local and national healthcare systems that have the potential to 
bring about dramatic gains in improving the health of the world’s populations. (W. Beasley, 
Starfield, van Weel, W. Rosser, & L. Haq, 2007) Investment must be done. A greatly increased 
commitment on the part of international organizations both within and outside of primary 
care is needed. (W. Beasley, Starfield, van Weel, W. Rosser, & L. Haq, 2007) Family doctors 
need time and infrastructures to develop clinical trials. That will be the only way to get 
answers to the questions that arise in family medicine context. In the future, eventually, the 
production of more high-quality work will gain the trust from editors. (L. K. Lam, 2004) 
Following there is a synopsis of Portuguese family medicine, focusing on relevant 
constraints and boundaries of this discipline, to help us understand how clinical trials can or 
cannot flourish within this specific environment.  
 
2.1 Worldwide Principles of Family Medicine 
 
Family Medicine, as stated by Ian R. McWhinney in his “A Textbook of Family 
Medicine”, is a body of knowledge characterized by a system of values and an approach to 
problems – that is identifiably different from that of other disciplines. In this same book he 
describes nine principles for this medical discipline: 
1. Commitment with the person rather than to a particular body of knowledge, group of 
diseases, or special technique; 
2. The ambition to understand the context of the illness; 
3. Every contact is an opportunity for prevention or health education; 
4. Single patients versus population groups – both must be addressed; 
5. The doctor as part of a community wide network of supportive and health care agencies; 
6. Ideally, doctors and patients would share the same habitat; 
7. Seeing patients in their homes is part of the job. Knowing the home give us a tacit 
understanding of the context or ecology of illness; 
I
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8. The importance of the subjective aspects of medicine. Doctor must be sensitive to 
feelings and have an insight into relationships; 
9. The doctor as a manager of resources. 
These nine principles are generally accepted to characterize Portuguese family 
medicine as well. 
 
 
 
 
2.2 Family Medicine in Portugal 
 
In Portugal this discipline started with non-specialist doctors but progressively 
evolved into something more. Currently it has a five year internship program (one general year 
common to all the other medical internships plus four vocational training years). 
Medical schools progressively created family medicine departments and the 
discipline itself is slowly conquering space in the medical courses curricula. Critical mass is 
being gained and highly respected strong personalities have arisen and can debate on equal 
foot with colleagues from other specialities. 
In the public sector, Portugal, as many other European countries, currently has its 
National Health Service divided in different levels of care: 
• Primary Care – where family medicine and public health is developed; 
• Secondary Care – hospital medical specialties; 
• Tertiary Care - where specific reference centres have its place as a last 
available resource. 
In family medicine clinical practice, the individual and family life cycle is fully covered, 
and as long as highly trained doctors assume their role, its quality is visibly growing every day. 
Unfortunately, family medicine still has an important handicap. Since politicians and 
the population generally ignore the need for specialized doctors in this field, it is still frequent 
to see non-specialized doctors practicing family medicine. 
The new generation of family doctors that is assuming permanent positions all over 
Portugal is accepted to be the most well prepared generation ever. Unfortunately there is a 
generalized doubt about the capacity of the country and its National Health Service to reap all 
the benefits it could from such qualified doctors. Underpaid, not fully recognized as a valuable 
human resource and deeply submerged in bureaucracy, these doctors tend to be pessimistic 
about their future and aren’t sufficiently stimulated to develop and assume as their own, 
techniques and many other skills that in some countries are considered an advantage and a 
stimulus to the daily clinical practice. 
According with ACSS data, in 2007, 71% of the health centre’s doctors were above 50 
years old and only 9 percent had less than 35 years old. (Carmo, 2012) It is important to 
describe the current status of the public primary care network.  The truth is that primary 
health care does not have grown in the proportion of the needs. (Carmo, 2012) 
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In the last years, there was a reform for this level of care, transforming some of the 
health centres in units oriented for objective accomplishment and pay for performance. This 
reform now, with the financial incapacity of the public budget (related with the economic 
crisis), is much slower than in the beginning and professionals feel that the network will 
probably be at least partially privatized - something that is not giving convincing results in 
other countries. 
In the current primary care public context, there are two different models for 
working in family medicine: UCSP (Unidades de Cuidados de Saúde Personalizados – En: 
Personalized Health Care Units) – the ones that work with no financial incentive and that 
employ the doctors who don’t want to work in a pay for performance model - and USF 
(Unidades de Saúde Familiar – En: Family Health Units) – the (at least in a more mature phase) 
pay for performance model. 
USF were created from voluntary candidatures from groups of doctors and other 
professional teams. They distinguish themselves, in the essential, from the UCSP, for the fact 
of having origin in a voluntary adhesion, having mandatorily an information system and, in a 
late phase, its remuneration regime being based in the professional development and 
incentives, and having a model of contracting and performance assessment. (Boquinhas, 2012) 
There are three types of USF models: A, B or C. The difference between the models 
results of the degree of organisational autonomy, the retributive model differentiation and 
incentives for the professionals, and the financial model and respective legal status. Model A is 
the less differentiated from the organisational point of view, corresponding to a kind of 
learning and improvement of the team work and on the first steps in techniques of 
contracting. Model B is the most suitable for teams with a greater degree of maturity and 
organisational development, also with greater requirement in the matter of contracting. 
Model C is intended to be a real contract program with clear objectives and a large degree of 
requirement in compliance. (Boquinhas, 2012) 
The population enrolled in each USF cannot be inferior to 4000 neither superior to 
18000. In the beginning of 2012 there were active in the “continental” Portugal 315 USF, from 
which 168 model A and 147 model B. Accepted for assessment, there were more 387 
candidatures that were waiting for an eventual order of approval. (Boquinhas, 2012) 
Even though it does attract many family doctors, the pay for performance model has 
weaknesses. Probably the most severe is that financial incentives come from general statistic 
process indicators, far from measuring the quality of the medical practice and, at times, even 
diverting professionals from the principles of family medicine. The clinical practice becomes 
more automatic and reduced to the accomplishment of some statistic objectives. This may 
ignore the patient itself and reduces the human touch and “art” in medicine. 
In UCSP it is important to refer that despite being a more conventional model of care, 
it still exists rigor in how they should work, especially as regards to the offer of a basic portfolio 
of services, hours of operation, well defined system of providing care and guidance of users, 
prescription renewal system, professional replacement system, liaison with other functional 
units of the ACES (Agrupamento de Centros de Saúde – En: Group of Health Centres), and a 
possible additional services portfolio. (Boquinhas, 2012) 
Common to UCSP and USF models, there is a great general weakness– the pressure 
to see patients in a short period of time. While it is true that this pressure is useful to increase 
the number of patients that have access to a family doctor when one is needed, it is also true 
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that the very usual Portuguese 15 minutes available for each consultation are not enough to 
satisfy all the patients’ needs. Some can say that in other countries the consultations are even 
shorter, but in those same countries, patients’ needs aren’t also totally satisfied. 
In the current days, a whole generation of family physicians over 50 years old is 
literally thinking about retirement. They are burned out and totally tired of bureaucracy that 
should have been delegated a long time ago to support personnel. The country does not need 
doctors dealing with bureaucracy. It’s a complete waste of money and highly qualified people. 
People with so much potential are the richness of a country. How can Portugal waste it like 
that? Stimulus is what this fine class of people need. Stimulus to take the best they are able to 
give. Who would not become burned out when with so much intellectual capacity sees nobody 
expects more from him than taking care of bureaucracy? Lately, Portuguese nurses have been 
asking to assume medical functions. They do not understand the real issue. It’s bureaucracy 
that doctors really need to delegate. That’s what doctors must delegate as soon as possible. 
Doctors need real clinical secretaries, trained for dealing with bureaucracy, letting for them the 
highly complex work for what they were trained for. 
In the private sector problems are different. There are the family doctors who work 
on their own as partners, and the ones who work for private larger institutions, as salaried 
family doctors. In either case, team work and continuous medical education tend to be 
forgotten. There’s also the problem of existing usually as non-organized and not-well defined 
units specifically for family medicine. It is common to include doctors trained in internal 
medicine or simply not specialized at all. Family medicine should be done by doctors 
specifically trained in family medicine. 
A good advantage of the private sector is the possibility of working with less time 
pressure (more flexibility to increase the quality, please and attract the patient), which can 
help in the doctor-patient relationship. 
Finally, in both public and private sectors, there is a common problem of 
communication between professionals. Notes in medical records tend to be scarce and 
unlinked; communication between several doctors from different areas and who serve the 
same patient is absent most of the time.  
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3. Methods 
 
 
 
he original search regarding the status of Portuguese clinical trials, its obstacles 
and opportunities comprised the electronic bibliographic international database 
MEDLINE. The keywords were: Clinical Trials; Europe; Family Medicine; General 
Practice; Portugal. Relevant papers, with same keywords but in Portuguese were also 
indentified in the only journal dedicated to Portuguese Family Medicine - RPMGF (previously 
titled RPCG). Due to the scarcity of either international or national articles found about this 
topic, a search was made on Portuguese health policy textbooks and national health plan 
policy documents looking for any material relevant to trials in family medicine. Mass Media 
were also consulted. The regulatory agency responsible for the approval of such trials, 
INFARMED, was also contacted and their reports about clinical trials were analysed.  At the 
end, this thorough search produced very limited secondary and tertiary information (because 
such information is indeed scarce even at European level). Therefore, it was necessary to talk 
with the actual protagonists of family medicine clinical trials in Portugal. The family doctors 
themselves were asked to answer to questionnaires. Three questionnaires gathering new data 
shared on this thesis were submitted to web (email) based discussion groups composed of 
family doctors (and family medicine trainees), i.e. MGF XXI, MGFamiliar, MGFClínica and 
EURACT-PT, and using the social network Facebook.  The few family doctors who actually have 
conducted clinical trials in Portugal were approached. Besides, fifteen Key Opinion Leaders  
were questioned about ways of developing Clinical Trials in Portuguese family medicine. 
 
T
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4. Results 
 
 
4.1 Literature Review and Interviews on 
Family Medicine Clinical Research 
 
 
 
 
In 2007, a report prepared by OECD about the assessment of Higher Education in 
Portugal and the strategic government document “Compromisso com a Ciência” marked the 
beginning of a remarkable evolution of the scientific Portuguese system. This is put in evidence 
as an increase in the following indicators: 
• Number of active researchers; 
• Number of graduates in mathematics, sciences and technology; 
• Number of new doctorates; 
• Public and private investment in research and development; 
• Number of international scientific papers; 
• New patent submissions. 
 
Besides the favourable evolution of these indicators, important university legal 
regime reforms were done promoting the internationalization of the Portuguese scientific 
system by establishing agreements for partnership with global reference institutions. (Campos 
& Simões, 2012) 
Research in the health area has currently the following funding options:  
• Public – fundamentally by the Ministry of Science and Techonology through FCT 
(Fundação para a Ciência e Tecnologia); 
• Foundations – usually with their own agenda (Fundação Gulbenkian, Fundação 
Champallimaud, Fundação Francisco José dos Santos, Fundação Bial); 
• Pharmaceutical Industry, including Contract Research Organizations.  
• International Funding – particularly through the European Union funds; 
• Patronage – unfortunately far from as common as in USA or UK; 
• Personal or own institution funding – not probable in the current context. A possible 
alternative is to contract research with appropriate incentives; 
• Scientific Societies – many times with pharmaceutical funds; such funding rarely seeks 
to encourage new projects or groups. (Antunes, 2010) 
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An important note is that most of these favourable indicators and the majority of the science 
funding in the health arena go to basic research (i.e. at molecular level) or animal (pre-clinical) 
research, rather than clinical research. 
In Portugal, until 2004, there was no national ethics committee. Its creation, (the 
national ethics committee is named CEIC) in that year was an important step to enable Clinical 
Trials nationwide. However, for a while although there was a national ethics committee there 
were no local ethics committees specifically for primary care, e.g. in ARS (Administração 
Regional de Saúde - Regional Health Administration), like there were in hospitals. 
According to INFARMED data, from 2006 to 2011 there were only four health centres 
involved in clinical trials:  Lapa (2 trials), Eiras (1 trial), USF Briosa (1 trial), and USF Santo André 
de Canidelo (1 trial).   This is a meagre and dramatic reality where nationwide clinical trials in 
primary care can be counted using hands.  Following are two examples of these rare units 
where clinical trials were performed.  
 
 
4.1.1 Comprehensive Clinical Trials Report by PwC 
 
In June 2013, PricewaterHouse Coopers (PwC) presented a report asked by 
APIFARMA entitled “Ensaios Clínicos em Portugal” (En: “Clinical Trials in Portugal”). While this 
report was not specifically focused on the Family Medicine setting, given the detailed 
description and analysis of the Portuguese context in regards to clinical trials, it was 
considered necessary to present some interesting data that the report describes. 
This report confirms the dramatic decrease in the number of clinical trials that were 
submitted in Portugal between 2006 and 2012 – 26% decrease (from 160 trials to 118 trials). 
The historical minimum since 2006 was achieved in 2011 with just 88 trials. The rate of clinical 
trials per one million inhabitants is one of the lower ones in Western Europe. 
As recommendations, PwC report highlights the following as some of the most 
significant: 
• Modification of the current legislation in order to reduce the timings between 
submission of trial proposal and the actual beginning of the subject recruitment – 
something considering highly limitative for clinical trials in Portugal; 
• Training of clinical trial centres for conducting the activity, namely through the 
creation of dedicated structures and by promotion of a larger integration and 
cooperation between stakeholders; 
• Creation of adequate incentives to promote the involvement of researchers and other 
professionals in clinical trials. 
 
This study presented in June 2013, also concluded that for each €1.00 invested in 
clinical trials there is €1.98 return for the Portuguese economy. The problem is that return is 
not being availed.  In fact, as it was mentioned by João Almeida Lopes (APIFARMA President) in 
2012, the pharmaceutical companies’ investment for Clinical Trials in Portugal was calculated 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
24 
in 36 million Euros. That, by itself, contributed for savings of 3.5 million Euros on the public 
expenditure related with medication and exams. (Diário Económico, 2014) 
But the problem with Clinical Trials is not just related with Portuguese Family 
Medicine. As João Almeida Lopes (APIFARMA President) says, Portuguese Clinical Trials as a 
whole would be improved if there was a review on the legislation that allowed a reduction of 
the timings between clinical trials’ submission for approval and the actual recruitment start. 
(Diário Económico, 2014) 
 
 
4.1.2 The Decline of the “Doctor-Scientist” 
 
As João Lobo Antunes states in his “Investigação Científica e Plano Nacional de 
Saúde” (2010, En: ”Scientific Research and the National Health Plan”), one of the problems 
about research in Portugal is related with the decline of the “doctor-scientist” which is seen 
since at least the 1980’s. 
This issue is a true obstacle felt everyday by any doctor and this is especially seen in 
the family medicine setting. The clinical work has swallowed the scientific work. Without the 
last one, will the doctor maintain his characteristics? What happened to the “doctor-
scientist”? Why this happened? 
According to João Lobo Antunes, this happened because: 
1. Current faster scientific progress compared to the past makes it harder to a doctor who 
wants to dedicate himself simultaneously to research and clinical work; 
2. Demanding management models, combined with doctors scarcity and high clinical goals, 
turn it difficult to make both clinical and research work; 
3. There’s a medical education with insufficient focus in the scientific component and an 
internship that tends to be long and not to value research, associated with the absence 
of role models in the clinical units – progressively faraway from the academic world; 
4. There’s a weak academic reward. This is specifically visible when realizing the fact that 
teaching and research have a too small importance in the medical careers progression. 
5. It is difficult to obtain financing, for example, because basic research projects tend to be 
more competitive; 
6. Does not exist support units to research, namely for clinical trials execution, bio 
statistical support or electronic medical notes / databases; 
7. There’s a complete absence of research priority in the strategy of the Health Units. 
The decline of the “doctor-scientist” is tragic for Medicine. It is our responsibility to 
invert it and bring medicine to its own place. Society needs doctors linked to the highest 
scientific standards. The new generation must create a new model for practicing medicine and 
become new role-models for the future generations. People like our last Medicine Nobel Prize 
Egas Moniz are needed. Portuguese medical schools need them and actually are able to 
generate new “doctor-scientists”. 
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Western medicine was not always as scientific as currently. Even in the beginning of 
the 20th Century, myths and beliefs were not totally eradicated. Empirical approaches were not 
unusual and the evolution was slow. Things have changed and an intense effort is being done 
in order to advance research. 
A long way is still ahead. The truth is, many drugs currently approved are not 
scientifically supported for the way they are used (e.g. off label) and even so, they can be 
authentic “best-seller” drugs. The only explanation for this fact must be that doctors still are 
not as scientific in their approach to patients’ treatment as they should. Pharmaceutical 
industry marketing probably is involved on it. It “sells” catchy sentences that appeal to the 
empirical and the non-scientific approach to patients’ treatment. The inattentive doctors, not 
savvy on research, can easily be manipulated and become almost as puppets in the 
pharmaceutical industry hands. That, for sure, will not be good for the communities and 
patients. 
To counter this problem, movements like the ones associated with evidence-based 
medicine and rational prescription are spreading a message of scepticism and rational analysis 
of the science behind the clinical work. Evidence-based medicine must take the place of 
“eminence-based medicine” or simply “faith-based medicine”. 
A way to improve family medicine is to make it as scientific as possible, moving it 
away from the myths and beliefs that have a capacity to resist by habit and persist even with 
nothing tangible to support it. 
Doctors must be educated as researchers since their most basic education, as non-
believers. Believing is enemy of science. Scepticism is the key. In a scientific world, the mind 
must be open to doubt and to question everything. No dogmas are allowed. The answer must 
be found through the old well known scientific method. That’s where research, and specifically 
clinical research, enters and has one of the main roles. 
There are many modalities to do clinical research: observational, experimental, 
transectional, longitudinal... Researchers are plenty of options to work on. It all depends on 
the question you are dealing with. 
It’s true that it’s not with a single study that you can assure anything but, if the result 
comes over and over every time you test the hypothesis, the odds of being right get bigger. It’s 
the repetition of the same phenomenon over and over that makes it plausible through the 
scientific method and that’s when evidence-based medicine comes with its metanalysis giving 
us even stronger evidence by stratifying the current state of the knowledge on a certain theme 
and offering new and fresh research questions. 
It’s in this ambient that ideally a country would like its doctors to be grown up. In it, 
patients are better assessed and treated. With a scientific medicine it is guaranteed that life 
expectancy and even more important, the quality of life, will grow. And the good news is that 
this pays for itself. With a scientific approach, superfluous treatments are eradicated and 
secondary effects resulting from useless drugs are prevented. This is, in fact, the basis for 
quaternary prevention concept – the prevention of iatrogenesis. 
What if we think about economy? What can a country gain with a more scientific 
family medicine? Besides a more active population, the country can also be able to create 
drugs and other devices that can then be commercialized with others and be a fountain of 
wealth. A stronger economy will arise. Even if it never develops a new drug, a country that 
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invests in clinical trials will attract pharmaceutical industry funds and create highly qualified 
jobs. 
General practice/family medicine research is also necessary to increase the 
attractiveness of general practice/family medicine to medical students and graduates. 
(Hummers-Pradier E. e., 2009) In times when Portuguese family medicine is so constrained 
when it comes to human resources, this must be taken in account. 
What about patients’ satisfaction? Helping other patients throughout the world will 
be a reason for satisfaction. If not for such an altruist reason, patients’ satisfaction will arise 
from the fact that their being seen by top doctors who do research and presumably are aware 
of the better options for solving their specific problems. Patients will also know that, if needed, 
they will have the opportunity to test new more advanced therapies in a secure and controlled 
environment. 
The 21st century should be a golden age of family medicine research because the 
time is right for our discipline, the health care environment is most suitable, and stakeholders 
are supportive. (L. K. Lam, 2004) Research in the Portuguese primary health care must be at 
the forefront of innovation. We need to think globally, instead of investing only in local 
studies, it is necessary to seek and establish the right partnerships and find the necessary 
funds and infrastructures. (Braga, 2011) The return of the doctor-scientist is a priority. It would 
not be reasonable to waste an intellectual elite like Portuguese family doctors. A country like 
Portugal cannot afford that. 
 
 
 
4.1.3 Subjects recruited in Primary Care Settings 
 
 
When recruiting subjects, the investigator have to take into account that many times, 
in primary care settings, patients suffer from less severe clinical conditions and are more 
heterogeneous both in demographic and in  clinical characteristics when compared with 
patients recruited in secondary care settings. They may have a lower probability of disease, or 
the disease may be diagnosed at a less severe stage, and they often report undifferentiated 
symptoms. Thus, restrictive selection criteria may result in limited applicability of the trial in 
primary care. (Lionis C, 2012) Armando Brito de Sá confirmed that this was one big problem in 
a clinical trial he was involved in still in the 1990’s at Centro de Saúde de Sete Rios. While this 
heterogeneity can be problematic for phases II, III or IV, where criteria selection must take into 
account these facts, it is also true that healthy patients ideally and usually do not recur to the 
secondary care. So we can admit the characteristics of primary care patients can be both a 
challenge and an opportunity. Family physicians must know how to best deal with it and make 
it always an advantage. The design of a randomized clinical trial in primary care should 
explicitly consider diversity in factors such as age range, participants’ levels of education, 
economic status, and multi-morbidity. Exclusion criteria should be kept to a minimum. The fact 
is - recruiting patients from a variety of primary care settings can assist in creating a valid 
sample. (Lionis C, 2012) If you keep this in mind, clinical trials will have high quality. 
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4.1.4 Challenges 
 
The problem with clinical trials in Portugal is not exclusive to family medicine, 
although it is more severe in this speciality. In fact, it crosses all of the Portuguese medicine. 
Note figures 1 and 2. 
In September 2012 Agência Lusa reported that clinical trials occurring in Portugal 
were falling since 2008. In 2012, in the first six month there were 53 new clinical trials 
registered versus 108 in the equal period for 2005. These are total numbers representing all 
the research areas. It means that if family doctors want to improve clinical trials, they will have 
to face an adverse setting. However, isn’t it true that it is in the hardest times that the best of 
our characteristics must come to surface and make us surpass the obstacles? 
 
 
Figure 1 – Map of Clinical Trials in Europe (Source: ClinicalTrials.gov consulted Jan. 2012 for Year 2011) 
 
 
For Peter Villax, responsible for innovation at Hovione, the main obstacle to clinical 
research in Portugal is the intervention of the CEIC. With the aim of protecting the health and 
safety of patients, CEIC have much preferred to err on the side of caution that today there are 
virtually no clinical trials in Portugal. There is the need for a balance between the desire to 
protect patients and the need to discover, test and develop innovative new treatments. (Diário 
Económico, 2014) 
The current panorama is not an easier one to overcome. In Portugal, even 
considering all health field clinical research, there is: 
• A negligible number of academic trials; 
• Almost no support infrastructures or training; 
• Inefficiently used electronic health records; 
• A research weakly linked to medical careers; 
• An uniformed isolation internally and externally; 
• An already complex EU regulation that is compounded even more; 
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• Scarce funding for clinical research. 
 
Even considering commercial clinical trials, Portuguese numbers are incomparable 
lower to the ones USA, European Union or BRICs have, already taking in account the dimension 
factor. 
 
David Silvério Rodrigues, a Family Doctor working at UCSP Torres Vedras (Extensão 
Silveira) in February 2014 questioned his peers about what was hampering clinical research in 
Portugal. He obtained 21 answers and concluded that there were basically two distinct types 
of reasons: 
1. Absence of research culture (with no research policies implemented; no specific legal 
statute for being PhD Student and Senior Doctor; no time for doctors to do research; 
absence of acknowledgment for the importance of research; no team work; low 
importance for curricular purposes); 
2. Weak or even total absence of resources and funding (with not enough grants 
available; not appropriate education for research; dearth of clinical research centres; 
long waiting times for approval for research studies). 
Still on the context of the question made by David Silvério Rodrigues, I would like to 
highlight three different visions from three different Portuguese family doctors: Mónica 
Granja, Frederico Rosário and Tiago Sousa Veloso. I chose them because from the answers I 
had access to, its assertiveness was especially striking. 
Mónica Granja reported seven reasons contributing for the hampering of Clinical 
Research in Portugal: 
1. Work in ethics committees done within the free/leisure time of its members; 
2. Multicentre trials with the need for the approval of multiple ethics committees, each 
with its own requirements and working with different timings; 
3. Still for multicentre trials, the for the authorization from multiple committees and 
people, as for example clinical councils, surgery coordinators and local research 
committees; 
4. Absence of the specific legal statute for being PhD Student and Senior Doctor (as it 
exists for trainees); 
5. The fact of PhD being very expensive; 
6. The lack of acknowledgment for research  skills as something that should be done by 
doctors in the Portuguese NHS; 
7. The overwhelming clinical workload given to doctors, namely the younger ones. 
Frederico Rosário, in turn, highlighted three measures he believes could help 
changing the clinical research panorama in Portugal: 
1. Acknowledgment of the importance of research, namely by providing doctors with 
time for it and giving support to get education for research; 
2. Faster timings for the approval of trials (by Ethics Committees and CNPD); 
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3. Availability of staff dedicated just to give support to statistics work as well as helping 
out on the design and analysis of the trials. 
Tiago Sousa Veloso also pointed out three possible solutions: 
1. Faster timings for the approval of studies; 
2. Full implementation of the rules for the legal statute of the registrar-PhD student, not 
forgetting mechanisms for support of research, 
3. Discourage research just for curriculum purposes and instead promote quality 
research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2– Clinical Trials in Europe - Portugal at the European Bottom (Source: ClinicalTrials.gov consulted  Jan. 
2012 for Year 2011) 
 
Impeding the conduction of clinical trials, the obstacles are enormous and seem 
almost insurmountable at times: 
• Absence of a structured strategy for clinical research; 
• Weak education in the research field; 
• Absence of structured teams; 
• The pressure to see the maximum number of patients; 
• The excessive time spent in bureaucratic activities; 
• The lack of support personnel; 
• The lack of infrastructures; 
• The lack of financial incentives; 
• No clear rules for compensation of the time invested in research; 
• The bureaucracy dealing with Infarmed, CEIC or CNPD (Comissão Nacional de 
Protecção de Dados - Data Protection National Commission) - too overwhelming for 
the time available to doctors, especially for those outside Lisbon who cannot deal 
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directly with the regulatory managers at Infarmed, CEIC or CNPD. The process is slow 
and with too many obstacles. 
 
Doctors willing to do investigator-initiated (academic) clinical trials are mostly on 
their own. There are: 
• No clinical research unit, infrastructures, or meaningful support at most health units; 
• No statisticians on staff to help; 
• No IDS pharmacists; 
• No research nurses; 
• No database managers; 
• No regulatory affairs managers; 
• No pharmacovigilance managers; 
• No marketing recruiters; 
• No monitors; 
• No administrative assistants; 
• No funds to hire CRO to compensate for lack of all the above; 
• No funds for regulatory approval fees; 
• No insurance funds; 
• Etc. 
 
Strategies for promoting primary care research in less economically developed 
countries like Portugal, should take into account the fact that clinicians are often overwhelmed 
by clinical demands in truly chaotic systems. (W. Beasley, Starfield, van Weel, W. Rosser, & L. 
Haq, 2007) The political agenda is to pressure ARS and ACES executive directors to increase the 
number of visits and number of listed patients per doctor. 
Another important issue to deal with is the suspicion by some good doctors that all 
industry clinical trials are biased and automatically “not relevant”. The truth is that, with 
regulation, pharmaceutical industry has a word to say and contributes to very meaningful 
research. 
In Portugal, only with great perseverance can a family doctor go forward with a 
clinical trial. Leaderships usually see clinical research as a secondary aspect. Even medical 
education is many times seen as useless for the quality of the service they rule. The big focus 
for management is almost inevitably on the clinical activities. Patients must be seen and that’s 
basically almost everything. Going against this ingrained way of thinking is “very tiring”. 
The isolation of primary care from the academic health centre, the usual site for 
clinical research, appears to further aggravate the delay between the discovery of new 
research findings and the adoption of those findings into practice. (Peterson, 2006) 
Armando Brito de Sá, from Faculdade de Medicina da Universidade de Lisboa states 
that one of the current problems with Portuguese family medicine research lies in the fact that 
an academic career is not as attractive as it should be, mainly for financial reasons. For him, 
fields of public recognized importance must be identified. The identified themes would be the 
guidelines for future clinical research in family medicine, so that governments feel it is 
important to finance it. Research lines are urgent to be established and followed. If the 
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promoter is academic or industry related is not important for him. Interaction is even possible 
as far as it is transparent, with well defined goals and deadlines.  
 
 
4.1.5 Opportunities 
 
Portugal also has positive points that can foster clinical research. One of it is the fact 
of Family Medicine trainees usually being encouraged to do more than medical consultations. 
Unfortunately, once a doctor becomes a specialist in Family Medicine, he no longer has the 
same flexibility to manage his non-clinical work. We can make research education more solid 
and give trainees a more supportive context to grow after the vocational training. 
Also positive the fact that In Portugal there are many patients from ethnic minorities 
in certain health centres. They are attractive for the pharmaceutical companies which desire to 
test drugs in representative samples of the general population. 
It is important to underline other relevant opportunities like the ones promoted by 
ECRIN (European Clinical Research Infrastructures Network), PtCRIN (offspring of ECRIN) or 
PNEC (INFARMED drug agency´s clinical trials platform). 
It is also not negligible recent funding and training programs for clinical research. 
Besides, the lack of support to health units and investigators wishing to conduct 
clinical trials can be addressed by creating a network of academic CROs. Academic CRO’s like 
Nova Medical School CRU - Clinical Research Unit can support academic clinical trials of doctor 
investigators from Nova´s affiliated teaching health units and PtCRIN. 
 
  
4.1.6 Three Cases of Clinical Trials in the Portuguese 
Family Medicine  
 
By 2006, one of the first clinical trials in a primary care setting was done in Portugal. 
It was at Centro de Saúde da Lapa, in Lisbon. The pharmaceutical industry was the sponsor. 
GlaxoSmithKline (GSK) was the one, doing it in an international clinical trial for its vaccine for 
the human papiloma virus (HPV). According to Alexandra Bordalo (from GSK), during a 
conference in 2006, one of the most complex and time expending issues was the financial 
contract. Those issues were responsible for a significant delay in the beginning of the subjects’ 
recruitment in the Portuguese sites due to heavy bureaucracy. 
In 2012, there was a Phase III clinical trial with empagliflozin promoted by 
Boehringer-Ingelheim. This molecule was being tested for Diabetes Mellitus and one of the 
research sites was USF Santo André de Canidelo (ACES do Grande Porto VIII – Gaia). By the 
time the Unit was approached for this thesis, Fernando Ferreira was the coordinator of that 
primary care unit in the Portuguese National Health Service. According to him, one of the main 
difficulties emerged from the generalized doubt about their capacity to participate in this 
clinical trial. Also, bureaucracies with the local ACES, ARS, CEIC and Infarmed were a problem. 
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Once more the time for obtaining answers from those institutions was too lengthy and when 
that happens, opportunities are simply lost. 
According to Fernando Ferreira, the clinical research education is not accessible to 
everyone. He says not all the health units have infrastructures or material and not all the work 
teams feel motivated to work in clinical research doing phase II or III clinical trials. 
Also, the absence of financial protocols that provide justice and equity in the 
distribution of economic benefits for all the institutions and researchers involved is a serious 
unresolved problem. 
Fernando Ferreira stated that bureaucracy must be dramatically reduced. All the 
documentation and authorization process must be accelerated and a goup of Units with 
researchers must be developed. Education in clinical research must be enhanced and justice 
and equity for getting financial benefits must be guaranteed. 
In 2013, USF Santo André do Canidelo was expecting to begin a new clinical trial. 
Then, this unit was to be accompanied by three other sites in the Portuguese Primary Care 
context. It would be for a double-blinded clinical trial with two active drugs and a placebo. It 
would also be for Diabetes Mellitus. 
For Family Doctors who had already any previous experience with clinical trials it was 
created a second questionnaire that would be answered only by José Augusto Simões. This 
family doctor works at USF Marquês de Marialva, in Cantanhede (central region of Portugal).  
The sponsor for this clinical trial experience was Boehringer Ingelheim and it was 
asked for three major obstacles and three strategies to overcome the obstacles. 
About the three major obstacles, José Augusto Simões would say: 
• ARS authorizations; 
• Need for the implementation of an ethics committee at ARS; 
• Effort of the remaining professionals of the unit. 
About three strategies to overcome the obstacles, José Augusto Simões stated: 
• Phone calls clarifying doubts and pressuring the authorizations; 
• Elaboration of a concrete proposal for the constitution of an ethics committee; 
• Reunions for clarifying and provide training in good clinical practice. 
 
4.2 Current European Strategies to Increase 
Clinical Trials 
 
 
Researchers and practitioners stand to gain considerably from an integrated 
approach. (Thomas, Graffy, Wallace, & Kirby, 2006) Shared projects help participants to 
develop trusted relationships. 
Networks may reduce the work involved in developing partnerships because they 
reach into many organizations and institutions. (Thomas, Graffy, Wallace, & Kirby, 2006) This 
will not only benefit the academic research, the one promoted by the investigator, moved only 
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by the scientific spirit, but also the pharmaceutical industry promoted research. It will be much 
easier to establish protocols for multicentre studies. 
Primary care (and so family medicine), by its comprehensive nature, relates to other 
disciplines both inside and outside of medicine (e.g. sociology, anthropology, health 
economics, and industrial engineering); primary care researchers benefit through 
collaborations with each of this different fields of knowledge. (W. Beasley, Starfield, van Weel, 
W. Rosser, & L. Haq, 2007). 
That’s why EU organisms have a role to play. Below are mentioned some of them: 
• European Centre for Disease Prevention and Control (ECDC); 
• European Food Safety Authority (EFSA); 
• European Institute of Innovation and Technology (EIT); 
• European Medicines Agency (EMA); 
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 
• European Research Council (ERC); 
• Executive Agency for Health and Consumers (EAHC); 
• Research Executive Agency (REA). 
As referred by Van der Zee, Kroneman and Bolibar in 2003, in order to obtain better 
results in clinical research it must be assured the existence of: 
• Scientific associations; 
• Peer-reviewed journal(s); 
• Defined population(s) resulting in population denominator(s) for practices; 
• A system for linking primary care to other health care services; 
• Departments and chairs of general practice at universities; 
• Integration of educational and research centres; 
• Clinicians working in group practices or health centres; 
• A certain degree of independence from the government; 
• Financial support for practicing clinicians to conduct research. 
 
In order to have high quality applied clinical research in primary care, Kekki in 2005 
summarizes it with the next three items: 
• Supportive climate; 
• Motivated researchers; 
• Adequate funding. 
A supportive climate is acquired with protected time for research functions, 
infrastructures and support staff availability. 
With supportive climate, it will be easy to find motivated researchers in a highly 
qualified and scientifically prepared generation of doctors who are embracing family medicine 
as their professional project of life. 
About adequate funding, in the current political and financial context Europe lives, 
from the public budget this will probably be hard to get. Instead, it can be found in the 
pharmaceutical industry or foundations. 
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4.2.1 European Networks 
 
 
Portuguese family medicine is connected with the European General Practice 
Research Network (EGPRN), an organization of General Practitioners / Family Doctors and 
other health professionals involved in research in primary care and family medicine. This 
network is part of the WONCA Europe structure and helps the collaboration and changing of 
ideas between researchers all over Europe. 
In fact, EGPRN already developed a Research Agenda for General Practice / Family 
Medicine and Primary Health Care in Europe which was written upon request of WONCA 
Europe. 
The Research Agenda focus in the main competencies and characteristics of Family 
Medicine, stating research needs and main action points. 
Below are the seven main topics worked out in this agenda: 
• To further develop and evaluate generic (person-centred, bio psychosocial, 
comprehensive or community-based) models or strategies; 
• To encourage comparative research in populations with different cultural, social, or 
geographic contexts and healthcare systems; 
• To promote and support longitudinal cohort studies to evaluate the prognosis and 
determinants of health and disease; 
• To promote and support intervention studies and randomized controlled trials  which 
take into account broad issues such as patient preferences, multimorbidity, quality of 
life and social and environmental circumstances; 
• To encourage research focusing on diagnostic strategies and reasoning; 
• To promote studies assessing effectiveness and efficiency in everyday care; 
• To develop and validate functional and generic instruments and outcome measures for 
use in GP/FM research and care. 
While this research agenda does not put clinical trials as a priority, it still has to be a 
reference to take into account whenever we think about research. 
Finally, the European Clinical Research Infrastructures Network (ECRIN) is an 
infrastructure supporting multinational clinical research projects all over Europe. This, not 
being specifically for family medicine context, can also be useful since it is an infrastructure 
that can help when trying to do multinational clinical research. ECRIN provides help to 
investigators and sponsors in preparing and conducting multinational clinical studies. That can 
be of great help because there are problems that are common to all the European countries.  
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4.2.2 The United Kingdom Case 
 
United Kingdom seems to be some steps ahead when we talk about clinical research 
in family medicine. With a National Health Service similar to the one Portugal has, it would 
always be important to look at. UK Primary Care clinical trials are developed in research 
networks. They have developed primary care research infrastructures that have been enabling 
and influential internationally. (Sullivan, Butler, Cupples, & Kinmonth, 2007) That’s how 
multiple relatively small health units interact to bring up good science.  Research networks 
offer a managed approach to hosting high quality research in the health service assuring 
recruitment and retention of study participants. (Sullivan, Butler, Cupples, & Kinmonth, 2007) 
This approach is apparently giving good results. Making part of a wider initiative, it was 
established one primary care research network for the whole country, which includes six topic 
specific networks and a comprehensive clinical research infrastructure through which service 
support, research governance, and academic staff is funded. (Sullivan, Butler, Cupples, & 
Kinmonth, 2007) 
The England wide primary care research network comprises central coordination for 
eight distinct local networks, like it could be done in Portugal. These networks link interested 
practice teams and local academic units of general practice to participate in a wide range of 
national projects led from the service, universities, and industry. (Sullivan, Butler, Cupples, & 
Kinmonth, 2007) 
Additionally, a National School for Primary Care Research was established in 2006. 
(Sullivan, Butler, Cupples, & Kinmonth, 2007) This was for sure a good step to stimulate 
research in this context and carries, of course, an important intrinsic signal – primary care 
research is crucial and there’s the intention to support it. From prevention to the management 
of long-term conditions, all the phases of health intervention are worked in England. 
Recruitment and retention strategies are also studied. 
Different ways of organising the networks will always be associated with different 
outcome profiles. A top-down, hierarchical approach based on institutional alliances and 
academic expertise attracts more funding and appears to be stable. The bottom-up, 
individualistic network with research practices is good at reflecting on practical primary care 
concerns. (Thomas, Graffy, Wallace, & Kirby, 2006) Both are defendable and have their own 
advantages. 
From June 2013 to May 2014, I worked in Northern Ireland which as part of the UK 
was an opportunity to better understand the UK reality. Although I worked in the secondary 
care, I couldn’t avoid noting the fact that it was very easy to get additional training in Good 
Clinical Practice. I was involved in a Clinical Trial in the field of Rheumatology and just before 
starting I easily had access to an Online Course with good quality training support. The Online 
option was a fine solution which turned out to be beneficial for the flexible schedule offered. I 
didn’t have to go anywhere and my learning rhythm was respected. 
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4.3 Questionnaires on Family Medicine 
Clinical Research  
 
4.3.1 “Portuguese GPs and the Clinical Trials 
Questionnaire – 2012” 
 
 
In order to understand and confirm whether identified problems and opportunities 
are indeed relevant to Clinical Research in the Portuguese family medicine context, a 
questionnaire entitled “Portuguese GPs and the Clinical Trials” (see attachment at the end of 
the thesis) was submitted in 2012 to family medicine specialists and trainees through e-mail 
based Portuguese family medicine forums (MGF XXI; MGFamiliar; EURACT-PT) These had the 
clear goal to characterize how Portuguese family doctors feel about Clinical Trials. 
Below, its results are described and analyzed from a total of 21 answered 
questionnaires. Two of the answered questionnaires were only partially completed, even in 
the “yes/no” questions, probably by distraction of those specific doctors. Two other doctors 
didn’t answered for one or another specific “yes/no” question, probably also by distraction. 
Most of the doctors didn’t answer to the open ended questions. 
 
 
Table 1 – Sample Characterization 
 Male Female 
Gender 9 (43%) 12 (57%)) 
 Trainee Specialist 
Career Stage 9 (43%) 12 (57%) 
 Until 45 Years Old Over 45 Years Old 
Age 15 (71%) 6 (29%) 
 
As it is clear by table 1, answers were obtained from a balanced gender and career 
stage sample. Most of the responders were below 45 years old. 
 
In the questionnaire there were twelve simple “yes/no” questions. Below, they are organized 
as they were stated in the questionnaire. 
1. Did you ever have an interest in conducting clinical trials? 
2. Are you aware of the regulatory requirements to conduct a clinical trial? 
3. Do you know how to deal with the experimental drug during a trial? 
4. Do you know what documents to submit to seek clinical trial approval? 
5. Do you know what good clinical (for research) practices are? 
6. Do you know the main rules and regulation to abide by during a clinical trial? 
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7. Do you know what requirements you must fulfil to close a clinical trial?  
8. Do you know where to go to educate yourself about such requirements? 
9. Does your health centre have infrastructures for conducting clinical trials? 
10. Would an academic career in clinical trials fulfil your role as a GP? 
11. Do you think that the country can benefit from clinical trials? 
12. Do you think the health system can benefit from clinical trials? 
 
 
 
As it is possible to confirm by the data presented, there is interest in conducting 
clinical trials. 
 
Figure 3– Did you ever had an interest in conducting clinical trials? 
 
 
Even less than 50% referring to be aware of the regulatory requirements to conduct a 
clinical trial, 43% is not that bad. 
 
 
 
Figure 4 - Are you aware of the regulatory requirements to conduct a clinical trial? 
 
 
Much more problematic is the fact that only 19% assume being certain that they 
know how to deal with regulations during a trial. Fortunatelly this for sure is an issue that can 
be resolved. 
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Figure 5 - Do you know how to deal with the experimental drug during a trial? 
 
 
 
 
 
From this questionnaire, it seems that most family medicine specialist/trainees also 
don’t know what documents to submit in order to approve a clinical trial (76%). 
 
 
 
 
 
Figure 6 - Do you know what documents to submit to seek clinical trial approval? 
 
Figure 7 presents interesting data. 
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Figure 7 - Do you know what good clinical (for research) practices are? 
 
Truth or not, a considerable number of family medicine specialists/trainees refer that 
they are aware of the Good Clinical Practices for research. There is the possibility of 
confounding Good Clinical Practices for research with others much more disseminated through 
family medicine doctors and related with the clinical work. 
 
 
Figure 8 – Do  you know the main rules and regulation to abide by during a clinical trial? 
 
 
The actual education and training given about research is still not enough. Clearly 
there is a lack of theoretical knowledge about the requirements to fulfil in order to close a 
Clinical Trial. From the ones who affirm to know, how much can really put in practice this 
knowledge, since their experience in clinical trials is scarce or simply none? 
 
 
Figure 9 - Do you know what requirements you must fulfil to close a clinical trial? 
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Figure 10 - Do you know where to go to educate yourself about such requirements? 
 
A considerable number (57%) state knowing where to get training, but probably are 
not motivated for education since in the next immediate question, 81% assume they don’t 
have any infrastructures in their workplace to help them develop research. 
 
 
 
Figure 11 - Does your health centre have infrastructures for conducting clinical trials? 
 
On a positive note, not having infrastructures to conduct clinical trials does not 
precludes doctors from totally excluding clinical research, since 43% believe an academic 
career in clinical trials could be interesting. 
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Figure 12– Would an academic career in clinical trials fulfil your role as a GP? 
 
There was not a single negative answer to the eventual benefit of clinical trials to the 
country, which means that it is accepted that by improving clinical trials, Portugal itself 
evolves. 
 
Figure 13 - Do you think that the country can benefit from clinical trials? 
What about the health system? Equal to the above question. 
 
Figure 14 - Do you think the health system can benefit from clinical trials? 
 
After the first twelve questions, I asked about agreement or not about some possible 
obstacles for doing clinical research. Once more, a “yes/no” answer was asked for. Below, I 
enumerate the possible obstacles to clinical research: 
• Pressure to see the maximum number of patients; 
• Lack of support personnel; 
• Lack of financial initiatives; 
• No clear rules for compensation of the time invested in research; 
• The bureaucracy dealing with INFARMED, CEIC or CNPD - too overwhelming for the time 
available to doctors, especially for those outside Lisbon who cannot deal directly with the 
regulatory managers at INFARMED, CEIC or CNPD; 
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• Once a doctor becomes a specialist in family medicine, he no longer has flexibility to 
manage his non-clinical work. 
 
 
Figure 15 - Pressure to see the maximum number of patients 
 
Most family doctors agree with the identified obstacles for clinical research. 
 
 
Figure 16– Lack of support personnel 
As can be seen above, all the answering doctors agreed with the lack of support 
personnel obstacle. 
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Figure 17– Lack of financial initiatives 
 
The same happened when asked about the obstacle related with not existing rules 
for compensation for the work invested in research. 
 
 
Figure 18 - No clear rules for compensation of the time invested in research 
 
 
 
Figure 19– The bureaucracy dealing with INFARMED, CEIC or CNPD - too overwhelming for the time available to 
physicians, especially for those outside Lisbon who cannot deal directly with the regulatory managers (...) 
 
The bureaucracy is clearly seen as an obstacle. Curiously, the answers about the non-
flexibility to manage non-clinical work after internship were very balanced. 
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Figure 20 - Once a doctor becomes a specialist in family medicine, he no longer has flexibility to manage his non-
clinical work 
 
After this sequence, it was asked for any other obstacle that possibly could be 
important to that specific family medicine specialist/trainee. 
 
In this respect, it was obtained six answers as additional obstacles: 
• Even prior to becoming a specialist, as a trainee, it is hard to reconcile schedules of 
“clinical work”, “academic work”  and family life”; 
• Patients’ compliance and no support from other doctors (colleagues) – colleagues say that 
they would never support another colleague that would like to do research if that were to 
interfere on “pay-for-performance style of a USF Model B”; 
• Her own preference in doing clinical work; 
• The division of time between university work and clinical work and the salary gap 
between the two careers, making research unattractive; 
• Lack of knowledge about this subject; 
• Whole team mindsets regarding feasibility of clinical trials in primary healthcare. 
 
 
In the “Portuguese GPs and Clinical Trials Questionnaire” which was done for this 
Master of Science Thesis in the beginning of November 2012, there were also questions about 
possible solutions or recommendations to improve clinical research in Portugal, as it is stated 
below: 
•  To put Clinical Research and particularly Clinical Trials in the political agenda;  
•  To establish a system of effective communication between clinical units and GP 
academic departments; 
•  To delegate some routine family physician functions to other health professionals in 
order to gain physician´s space and time for research and therefore not compromising the 
number of patient visits; 
•  To contracting support staff (statisticians, nurses, administrative, etc.) specifically for 
research; 
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•  To improve cooperation between clinical units and family medicine university 
departments; 
•  To  involve health care units in education and research networks; 
•  To give economical independence to health centres; 
•  To finance the practicing clinicians in order to conduct research; having protected 
time and being paid to work on studies; 
•  To obtain industry funds in a non-binding way to increase funds and support rooms, 
better equipment, even newer equipment, furniture, refurnishing walls, computers, without 
sacrificing the available budget. 
 
 
Again, the asked answers were “yes/no” ones. The results are below: 
 
 
Figure 21 - To put Clinical Research and particularly Clinical Trials in the political agenda 
 
 
 
 
The majority agrees with the importance of bringing clinical research and particularly 
clinical trials to the political agenda. 
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Figure 22 - To establish a system of effective communication between clinical units and GP academic 
departments 
 
All the obtained answers were favourable to establishing a system of effective 
communication between clinical units and GP academic departments. 
 
 
Figure 23 - To delegate some routine family physician functions to other health professionals in order to gain 
physician's space and time for research and therefore not compromising the number of patient visits 
 
 
 
A less expressive support was obtained to the possibility of delegating some routine 
family doctor functions to other health professionals. This probably reflects some 
apprehension due to recurrent and inconsequent attempts from nurses to get functions clearly 
not being qualified for that. 
 
 
Figure 24 - To contracting support staff (statisticians, nurses, administrative, etc.) specifically for research 
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As it can be seen above, contracting support staff is positive for most of the 
responders. 
 
 
 
Figure 25 - To improve cooperation between clinical units and family medicine university departments 
 
 
 
It was unanimous the support for improvements in the cooperation between clinical 
units and family medicine university departments. The same happened for the involvement of 
healthcare units in education and research networks. 
 
 
 
Figure 26 - To inlvolve healthcare units in education and research networks 
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Figure 27 - To give economical independence to health centres 
 
Curiously, receiving economical independence for the health centres wasn’t seen in 
such a unanimous way as it could be expected. 33% of the responders answered “No”. 
 
 
Figure 28 - To finance the practicing clinicians in order to conduct research; having proctected time and being 
paid to work on studies 
 
 
Unanimous was the answer to the possibility of receiving financial support 
specifically for conducting research and having protected time to work in studies. 
 
 
Obtaining industry funds was an option against which 52% answered, probably 
reflecting the scepticism, distrust and even demonization of the pharmaceutical industry 
between the Portuguese family doctors. 
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Figure 29 - To obtain industry funds in a non-binding way to increase funds and support rooms, better 
equipment, even newer equipment, furniture, refurnishing walls, computers, without sacrificing the available 
budget 
 
 
After this, it was asked for any other suggestions to improve clinical trials in a primary 
care setting. And for this question I would find only one answer: 
• Strong GP university departments, fully staffed, adequately paid, linked to collaborating 
health centres, both for teaching and research. 
 
 
 
Asked about the possibility of once more getting involved in a Clinical Trial, the 
answer was “yes”. 
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4.3.2 “Portuguese GPs and Clinical Trials Questionnaire – 
2014” 
 
In June 2014 another questionnaire was applied to family doctors and family 
medicine trainees from Portugal. This time, it was chosen to make a much simpler 
questionnaire in order to maximize the number of answers. 
It used online forums (MGFamiliar, MGF_XXI, MGFClínica, EURACT-PT), emails and 
the social network Facebook. 
There was no formal document and the questions were directly typed in the emails 
and on Facebook. 
Five questions were asked and 84 family doctors / family medicine trainees replied. 
It must be underlined that the answers were restricted to values between 0 and 20. 
 
The first question was the following:  
1. In a weekly work schedule of 40 hours, how many would you like to have just to 
work on Clinical Trials? 
 
Table 2 – Statistical Analysis for the answers to Question 1 
Number of Answers 84 
Maximum 20 
Minimum 0 
Mean 4.411 
Mode 5 
Median 4 
Standard Deviation 3.675 
 
 
As you may well see on the table above, with a standard deviation of 3.675, the 
mean was 4.411. Mode was 5 with the answers ranging from 0 to 20. Generally, it seems that 
once a week doctors would like to have a period of 4 to 5 hours to dedicate only to clinical 
trials. 
The next question was: 
2. Classify the importance that Clinical Trials should have in the daily work of a Family 
Doctor. 
 
Table 3 - Statistical Analysis for the answers to Question 2 
Number of Answers 84 
Maximum 20 
Minimum 1 
Mean 11,387 
Mode 15 
Median 11 
Standard Deviation 5,018 
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On the above table is quite clear that with a standard deviation of 5.018, the 
importance of Clinical Trials for Portuguese Family Doctors is something that tends to be 
variable. The mode was 15, which is quite high, but the mean was 11.387.  
 
Below is the third question: 
3. Classify how much do you agree with the use of scientific paper publication as 
criteria in the assessment of the Family Doctors 
 
Table 4 - Statistical Analysis for the answers to Question 3 
Number of Answers 84 
Maximum 20 
Minimum 0 
Mean 11,488 
Mode 10 
Median 10 
Standard Deviation 5,128 
 
 
The pattern of the answers is similar to the one observed for question 2 with one 
major difference. The mode here was 10. An hypothesis for this decrease, is the possible 
notion that in the current context, with the current conditions, scientific paper publication is 
very hard for a Family Doctor. Caring of the patients is their main role and the leaderships 
don’t really support doctors to routinely publish papers. 
 
 
Below is the fourth question: 
4. For the assessment of the Health Centre where you work, how much would you 
agree to have Clinical Trials development as criteria? 
 
Table 5 - Statistical Analysis for the answers to Question 4 
Number of Answers 84 
Maximum 20 
Minimum 0 
Mean 10,756 
Mode 15 
Median 10 
Standard Deviation 5,497 
 
 
In the above question, the observed pattern presents with an even higher standard 
deviation. Mode is once again 15, but the mean has a mild decrease.  
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The last question is below; 
5. If you had the support from the leaders of the Portuguese National Health Service 
and also a suitable structure, with how much motivation would you work on Clinical Trials? 
 
This is the question that would finally say what could happen in ideal conditions. The 
question intended to underline what would be the receptivity of Family Doctors to a change in 
the conditions for the work on Clinical Trials given by the Government of Portugal. 
 
Table 6 - Statistical Analysis for the answers to Question 5 
Number of Answers 84 
Maximum 20 
Minimum 4 
Mean 15,762 
Mode 20 
Median 17 
Standard Deviation 4,428 
 
 
Mode was an impressive 20 for a mean of 15.762. The Government of Portugal may 
well count on Family Doctors to collaborate if they choose to invest on the creation of suitable 
conditions for an improvement of the Clinical Trials panorama in Portuguese Family Medicine. 
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4.3.3 “Improving Clinical Trials in Portuguese Family 
Medicine” – The Vision of 15 Key Opinion Leaders 
 
Some Key Opinion Leaders were approached with the following question: 
List 3 ideas that should be implemented in order to improve the development of Clinical 
Trials in the Portuguese Family Medicine. 
Below it’s presented a table with the answers of the fifteen who accepted to 
collaborate and replied. 
Table 7 – The answers of the 15 Key Opinion Leaders Approached 
Key Opinion Leaders 
Three ideas to improve the development of Clinical Trials 
in the Portuguese Family Medicine. 
Dr Fernando Ferreira Good Clinical Practice Training 
(Coordinator of USF Santo André 
do Canidelo) 
Developing Research Networks 
  Paying for the research work 
  Speeding up the bureaucracy 
Dr Denise Alexandra 
Logistical support from the Ministry of Health, e.g. 
Protected time for Clinical Trials 
(Current Portuguese EURACT 
Council Member) 
Financial support from the Ministry of Health, eventually 
with honest and transparent partnerships with the 
Pharmaceutical Industry 
  Training for the professionals who want to do research 
Dr Luís Filipe Gomes Learning of research during vocational/specialty training 
 
Relevance of research in CME/CPD schemes 
 (Former Portuguese EURACT 
Council Member) 
Time and money allocated for researchers 
  Change of publishing politics 
Dr Vítor Ramos There must be a clear National framework and guidelines 
(Invited Assistant Professor at 
ENSP) 
There must be a National regulatory entity or regulatory 
body 
  
There must be enough independency in relationship to 
industry, mediated technically and in financial aspects by 
the National regulatory body 
Professor Luíz Miguel Santiago Strategic and population aim of scientific knowledge 
 
Infra-structural improvement of the Primary Care Units 
(Invited Associate Professor at 
UBI)  
Through fees improve the quality and the number of 
devoted scientists in the Primary Care setting 
Professor António Vaz Carneiro Protected time for research for Family Doctors 
(Professor at FMUL / Director of 
CEMBE) 
Direct financing for research in primary care 
  Creation of CROs in Primary Care 
Dr José Silva Henriques 
To sensitize the Ministry of Health for the importance of 
Clinical Research in Family Medicine Units, as it is essential 
for the quality of practice 
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
54 
(President of the College of 
Family Medicine at Ordem dos 
Médicos) 
To Promote next to Family Doctors, the importance of 
Clinical Research for quality, continuous improvement and 
advance of clinical practice 
  
To give time for Research, namely by inserting it in the 
Family Doctor work schedule, for those who take on the 
role of researchers in their Health Units 
Dr Raquel Braga Ethic discussion about clinical trials in Primary Care 
(Former Editor at RPMGF) Time and resources for the subject (financial and other) 
  Training only for those who are interested 
Professor José Manuel Silva 
Greater importance of Clinical Research in Family Doctors' 
CV 
 
Allocation of time for research 
 (President of Ordem dos 
Médicos) 
Elimination of excessive bureaucracies and speeding up 
response times by the involved entities 
  Financial retribution 
 
To promote training in clinical trials management, namely 
about defining timings, mechanisms and defining the 
structure and the logistics needed for the development of 
Clinical Trials in Primary Care at each Health Unit, trying to 
adapt the resource for clinical trials in this setting; 
Dr Luís Pisco 
To promote pragmatic clinical trials adequate to the 
reality of Primary Care and to the needs in Health, in 
particular effectiveness of the interventions in Health; 
  
To promote clinical research oriented  for the interests of 
the National Health Service and of the Health 
professionals namely through the creation and financing 
of support offices to Clinical Research in the ACES, through 
the harmonization of the care and research needs, the 
empowerment of the human and material resources for 
the development of that activity; 
(Vice-President of ARS de Lisboa 
e Vale do Tejo)  
Integration of the Primary Care Health Functional Units in 
national and international research networks in Primary 
Care, divided by thematic classes like respiratory diseases, 
arterial hypertension, depression, diabetes and 
musculoskeletal diseases; 
  
To establish objective conditions to receive clinical trials 
promoted by the Pharmaceutical Industry, through the 
creation of cooperation and partnership protocols 
between the Regional Health Administrations, 
Pharmaceutical Companies and CROs encouraging 
activities which give gains in training and clinical 
excellence for the professionals (at ARSLVT). 
Professor Jaime Correia de Sousa 
Family Health Units should be able to contract protected 
time for research, including CT with the Health Services 
Management. 
(Professor at Escola de Ciências 
da Saúde da Universidade do 
Minho) 
One or more members of the practice team should be in 
charge of promoting and managing research that should 
involve the whole team. 
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A National (or Regional) Institute of Primary Health care 
should be created aiming at Specific Training of Primary 
Health Care professionals, CME / CPD and Research. It 
should be closely associated with Academic Departments 
of Family or Community Health in Medical and Nursing 
Schools. 
Dr José Miguel Guimarães 
To speed up the approval of Clinical Trials in Portugal, 
namely by professionalizing a National Ethics Committee 
that analysis and replies within suitable timings and 
deadlines. 
(President of the North Regional 
Section of Ordem dos Médicos) 
To establish Clinical Research time in the doctor's 
schedule, e.g. 5 hours weekly, just for Clinical Research, 
namely Clinical Trials. 
  
To value adequately Clinical Research (including Clinical 
Trials) within the doctors' Curriculum Vitae (namely while 
recruiting) and within a Health Unit. 
Professor José Augusto Simões 
Good Clinical Practice Courses, for Clinical Trials, open to 
Family Medicine Trainees and Family Doctors. 
(President of ADSO) Creation of one Clinical Trials' Unit at each ACES 
  
Development of a structure at each ARS to deal with 
Promoters about everything related with Clinical Trials. 
Dr Carlos Martins Training in pragmatic research design and methodology 
(Founder of the Website 
MGFamiliar.net) 
Training in medical statistics 
  
Offering support of statisticians to primary healthcare 
researchers 
Professor Armando Brito de Sá 
A real payment, not included in the salary, just for family 
doctors who work on Clinical Trials, not dependent on 
absurd overheads established by the Ministry of Health. 
(Professor of Family Medicine at 
FMUL) 
Allocation of legal protected time for research in the 
profile of a Family Doctor (4-6 hours weekly). 
  
Acknowledgment, for a small number of Family Doctors, 
from the academic career of Family Medicine, permitting 
investment of time in the academic area without losing 
money (e.g., 7-8/10 of the week schedule dedicated to the 
academic area and 2-3/10 of the week schedule dedicated 
to clinical work). 
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5. Discussion 
 
 
linical Trials are very scarce in Portuguese Family Medicine but in the twenty 
first century you cannot isolate the Portuguese case from the rest of the 
European context.  
In literature review it was detected a networks model used in the United Kingdom 
and in the rest of Europe. Networks can help integrate academic research and service 
development initiatives by facilitating inter-organisational interactions. 
With research networks in Portugal linked between each other, included in a 
nationwide network and also interacting with equivalent ones from everywhere in the world 
we will be taking a step forward in order to increase the quantity and quality of Portuguese 
clinical research, particularly in the Family Medicine field. Clinical trials will be no exception. 
The mentioned European networks are essential for the success of Portuguese Family 
Medicine research. That’s also why we must send Portuguese representatives to the European 
existent structures. Our representatives can go and bring more knowledge and skills. 
Interacting with more experienced colleagues can also be a way of surpassing years of delay. 
Analyzing the questionnaires previously described, it is clear that while Family 
Doctors fear delegating some functions that are exclusively done by them, it is also true that 
they are very keen about the possibility of being more involved in research activities as Clinical 
Trials. It seems that while on the current context they effectively don’t do much research 
work, if the suitable conditions were provided and problems were corrected, they would in 
fact be happy to have hours on their own weekly schedule just for research. 
From the answers provided by the Key Opinion Leaders approached, it is easily 
understandable some key points, namely: 
• Time; 
• Money; 
• Support. 
There are weaknesses on the results of this thesis. The most participated 
questionnaire had 84 replies and the bibliography found about this subject is scarce. Although 
this is a fact, I trust this results represent new data about the subject and constitute the basis 
for a fundamental reform that happening would help improve the quality of health care in 
Portugal and, at the same time, represent more money for Portuguese economy. 
C
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6. Conclusion / 
Recommendations 
 
he return of the doctor-scientist must be a priority in order to ensure Portugal 
has better health care and a stronger economy. To improve Clinical Trials in 
Portuguese Family Medicine the Government of Portugal must provide time, 
money and support. Below there are twenty recommendations divided by this three very well 
defined areas for development. 
 
6.1 To Provide Time 
 
• To allow protected time for research to staff members; 
 
• To delegate some routine family doctor’s functions to other health professionals in 
order to gain doctor´s time for research and therefore, not compromising the number 
of patient visits (especially bureaucracy); 
 
• To encourage a sizeable number of Family Doctors into a parallel academic career, 
permitting investment of time in the academic area without losing salary money (e.g., 
7-8/10 of the week schedule dedicated to the academic area and 2-3/10 of the week 
schedule dedicated to clinical work). Family Doctors should not be punished 
economically because of an academic career.  
 
 
6.2 To Finance 
 
• To professionalize researchers, economically rewarding them for research work – an 
additional specific payment, on top of the salary, for Family Doctors who work on 
Clinical Trials; Funding and a salary for research is fundamental. This is an opportunity 
for extra compensation for poorly paid but highly qualified professionals without 
sacrificing patients’ time (e.g. working after hours on research); 
 
• To reward research work when assessing health units; e.g. in a model B USF, research 
can be put as value indicator, bringing more money and resources to the unit; 
 
T
Developing Clinical Trials in Portuguese Family Medicine – Challenges and Opportunities in the European Context 
Master of Science Thesis – Manuel Pedro dos Santos Rodrigues Pereira 
 
 
58 
• To increase the number of grants available from private and public nature. Direct 
financing for research in primary care must be a priority. Health Units should also be 
able to get direct financing for research from the Health Services Management; 
 
• To easily allocate industry and grant funds to specific units that effectively do research, 
instead of to the central/regional administration. This money could even be used to 
increase the quality of support rooms for research, obtain better or even newer 
equipment, furniture, and refurnishing walls, computers without sacrificing the 
available budget; 
 
• To facilitate industry promoted clinical trials. These will be important at least in the 
beginning; As soon as critical mass of researchers and know-how emerges, investigator 
(academic) research will become natural and will have its own funding also. 
 
 
6.3 To Support 
 
• To increase Family Doctors education for clinical research; trainees who want to be 
researchers must be adequately trained. The specialists must have the possibility of 
doing workshops and other specific courses, namely in Good Clinical Practice, 
pragmatic Research Design, Methodology, and Medical Statistics. This could be done by 
creating and developing a National Institute of Family Medicine aiming at specific 
training of Family Doctors, CME / CPD and research. It should be closely associated with 
Academic Departments of Family Medicine. A certain degree of separation and 
independence from the ministry of health is desired so that is better accepted by the 
Portuguese Family Doctors; Partnerships must be established between clinical units 
(with its research departments), education institutions and research institutions; 
 
• To improve the infra-structures for research within Family Medicine Units; specifically 
rooms for trial master files or for subject assessment; 
 
• To professionalize ethics committees and regulators specifically targeted for the need 
of Family Medicine research. This would  improve timings for approval of Clinical Trials, 
by Ethics Committees and CNPD; 
 
• To attract CROs and foundations for research in Family Medicine. Strategic and 
population aim of scientific knowledge must be valued because even if it is less 
pompous in its aims than basic research, generally does more to improve  the health of 
citizens immediately and profoundly; 
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• To develop a structure at each ARS to deal with Promoters about all issues related with 
Clinical Trials. To simplify the communication and administrative process with the ACES, 
ARS and the regulators in order to promote faster approval for Clinical Trials. In fact, 
each ACES should have its research office to give support on a local basis; 
 
• To establish and develop protocols for Clinical Trials. Standard procedures must be in 
place to receive Clinical Trials promoted by the Pharmaceutical Industry, through the 
creation of cooperation and partnership protocols between the Regional Health 
Administrations, Pharmaceutical Companies and CROs, encouraging activities which 
provide gains in training and clinical excellence for the professionals; 
 
• To create regional and national Research Networks and integrate international 
Research Networks. Networks could even be divided by thematic classes like 
respiratory diseases, arterial hypertension, depression, diabetes and musculoskeletal 
diseases; 
 
• To create a network for scientific literature access;  
 
• To place Clinical Research and particularly Clinical Trials in the political agenda. In order 
to make Portugal  assert itself as a valid player in the Clinical Research context, politics 
have the key role to change the current state of Portuguese clinical trials, taking 
advantage of an intellectual elite clearly capable of more and currently underused; 
 
• To define a research agenda, choosing strategic therapeutic areas to focus in the near 
future, possibly choosing pragmatic Clinical Trials adequate to the reality of Family 
Medicine and to the needs in Health, in particular effectiveness of the interventions in 
Health and the national health plan; 
 
• To contract support staff (statisticians, nurses, administrative, etc.) specifically for 
research. To choose one or more members of the practice teams to be in charge of 
promoting and managing research that should involve the whole team; 
 
• To value research activity in the medical career. It is fundamental to review the medical 
career in order to give more emphasis to research work, recognizing the medical work 
as an investigator (Medicine is also research.) It must be given relevance to research in 
CME/CPD schemes. 
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8. Attachments 
8.1. Attachment 1 – “Portuguese GPs and the 
Clinical Trials Questionnaire – 2012” 
 
 
 
 
 
 
 
 
 
This questionnaire is related to a Master of Science thesis by Manuel Pedro dos Santos 
Rodrigues Pereira and it has the objective of characterize how Portuguese GPs feel about 
Clinical Trials. 
 
Please, complete data on gender, age and if you’re a trainee or a specialist. 
 
Gender:           
 
Age: 
 
Trainee/Specialist:  
 
Below, there are some questions to be answered with a simple “yes/no”. 
 
1. Did you ever have an interest in conducting clinical trials? 
 
2. Are you aware of the regulatory requirements to conduct a clinical trial? 
 
3. Do you know how to deal with the experimental drug during a trial? 
 
Portuguese GPs and the Clinical Trials 
QUESTIONNAIRE 
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4. Do you know what documents to submit to seek clinical trial approval? 
 
5. Do you know what good clinical (for research) practices are? 
 
6. Do you know the main rules and regulation to abide by during a clinical trial? 
 
7. Do you know what requirements you must fulfil to close a clinical trial?  
 
8. Do you know where to go to educate yourself about such requirements? 
 
9. Does your health centre have infrastructures for conducting clinical trials? 
 
10. Would an academic career in clinical trials fulfil your role as a  GP? 
 
11. Do you think that country can benefit from clinical trials? 
 
12. Do you think the health system can benefit from clinical trials? 
Do you agree with the following obstacles for clinical research (yes/no)? 
 
• pressure to see the maximum number of patients 
• lack of support personnel 
• lack of financial initiatives 
• no clear rules for compensation of the time invested in research 
• the bureaucracy dealing with Infarmed, CEIC or CNPD (ComissãoNacional de Protecção 
de Dados) - too overwhelming for the time available to physicians, especially for 
those outside Lisbon who cannot deal directly with the regulatory managers at 
Infarmed, CEIC or CNPD. 
• Once a MD becomes a specialist in family medicine, he no longer has flexibility to 
manage is non-clinical work. 
 
Any other obstacle that is important to you: 
 
Do you agree with the following recommendations to improve clinical research in Portugal 
(yes/no)? 
 
• To put Clinical Research and particularly Clinical Trials in the political agenda 
• To establish a system of effective communication between clinical units and GP 
academic departments.  
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• To delegate some routine family physician functions to other health professionals in 
order to gain physician´s space and time for research and therefore not 
compromising the number of patient visits; 
• To contracting support staff (statisticians, nurses, administrative, etc.) specifically for 
research; 
• To improve cooperation between clinical units and family medicine university 
departments; 
• To  involve health care units in education and research networks; 
• To give economical independence to health centres; 
• To finance the practicing clinicians in order to conduct research; having protected time 
and being paid to work on studies.  
• To obtain industry funds in a non-binding way to increase funds and support rooms, 
better equipment, even newer equipment, furniture, refurnishing walls, computers 
without sacrificing the available budget. 
Any other suggestions to improve clinical trials in a primary care setting?  
 
Thank you very much. 
 
Until November 10
th
, 2012, please send back to: manuel_rodrigues_pereira@yahoo.co.uk 
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8.2 Attachment 2 – “Doing Clinical Trials in 
the Portuguese Family Medicine Context” 
 
 
 
 
 
 
 
 
This questionnaire is related to a Master of Science thesis by Manuel Pedro dos Santos 
Rodrigues Pereira and it is intended to characterize how Portuguese GPs who ALREADY did 
Clinical Trials feel about it. 
 
 
Please complete the following data: 
 
Gender:           
 
Age: 
 
Trainee/Specialist:  
 
Unit where the Clinical Trial was done: 
Doing Clinical Trials in the Portuguese Family Medicine Context 
QUESTIONNAIRE 
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Sponsor (Pharmaceutical Industry/Investigator Iniciative): 
 
 
 
Below, there are some questions to be answered: 
 
• Three major obstacles: 
 
• Three strategies to overcome the obstacles: 
 
• Would you like to do get involved in another Clinical Trial (yes/no)? 
 
 
Thank you very much. 
 
Until November 10
th
, 2012, please send back to: manuel_rodrigues_pereira@yahoo.co.uk 
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8.3 Attachment 3 – “Clinical Trials and The 
Portuguese GPs Questionnaire – 2014” 
 
This questionnaire is related to a Master of Science thesis by 
Manuel Pedro dos Santos Rodrigues Pereira and it has the 
objective of characterize how Portuguese GPs/Family Doctors 
(including trainees) feel about Clinical Trials. 
 
 
Using a number from 0 to 20, answer the following questions: 
 
 
1. In a weekly work schedule of 40 hours, how many would you like 
to have just to work on Clinical Trials? 
 
 
2. Classify the importance that Clinical Trials should have in the 
daily work of a Family Doctor. 
 
 
3. Classify how much do you agree with the use of scientific paper 
publication as criteria in the assessment of the Family Doctors. 
 
 
4. For the assessment of the Health Centre where you work, how 
much would you agree to have Clinical Trials development as a 
criteria? 
 
 
5. If you had the support from the leaders of the Portuguese 
National Health Service and also a suitable structure, with how 
much motivation would you work on Clinical Trials? 
 
 
Thank you very much. 
 
Manuel Rodrigues Pereira 
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8.4 Attachment 4 – “Improving Clinical Trials 
in Portuguese Family Medicine” - The Vision 
of 15 Key Opinion Leaders 
 
 
 
The following question is related to a Master of Science thesis by Manuel 
Pedro dos Santos Rodrigues Pereira and it has the objective of finding 
solutions to improve the development of Clinical Trials in the Portuguese 
Family Medicine. 
 
It is very likely to quote your answer in the thesis, so by answering it, you 
understand that you are also authorizing the use of your answer associated 
to your name. 
 
• List 3 ideas that should be implemented in order to improve the 
development of Clinical Trials in the Portuguese Family Medicine. 
Thank you. 
 
Manuel Rodrigues Pereira 
 
